ABSTRACT
Background:
Rituximab is a chimeric monoclonal antibody targeting CD-20, which is a B cell surface antigen. Autoimmune vesiculobullous diseases, connective tissue diseases, graft-versus-host disease and vasculitis are the main categories of dermatoses for which rituximab has shown successful clinical applications. Infusion reactions and infections are the most common adverse-effects. This review summarizes the pharmacology, mechanism of action, clinical uses and adverse effects of this promising agent.
